Mottiwala Aziz 4

What Happened

• Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals (TARS), received two equity awards on March 5, 2026: 30,724 option-type awards and 19,306 restricted stock units (RSUs), for a total of 50,030 shares. Both awards were reported at $0.00 per share (compensation grants/derivative awards), not open‑market purchases or sales.

Key Details

• Transaction date: March 5, 2026; filing date (Form 4): March 9, 2026 (filed timely).
• Reported price: $0.00 per share (awards/grants).
• Shares/awards granted: 30,724 (options) + 19,306 (RSUs) = 50,030 total.
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes:
  • F1 (options): 25% vest on March 5, 2027, then 1/48th of the option shares vest each month thereafter for 3 years, subject to continuous service.
  • F2 (RSU definition): Each RSU represents a contingent right to one share of common stock.
  • F3 (RSU vesting): RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, subject to continuous service.
• Transaction type code: A = Award/Grant (derivative awards). No sale, purchase, or exercise reported.

Context

• These are compensation grants, not open-market buys or sales, so they reflect company compensation practices rather than an immediate trading signal. The options have a multi-year vesting schedule and the RSUs vest annually over four years, meaning the economic benefit is contingent on continued service and future vesting.